Symbols

RVTY

Revvity·NYSE

--(--)

RVTY fundamentals

RVTY Q4 2025 Earnings

Revvity (RVTY) released its earnings on Feb 2, 2026: revenue was 772.06M (YoY +5.82%), beat estimates; EPS was 1.7 (YoY +19.72%), beat estimates.

Revenue / YoY

772.06M

+5.82%

EPS / YoY

1.7

+19.72%

Report date

Feb 2, 2026

RVTY Earnings Call Summary for Q4,2025

Revenue Growth: FY2025 organic +3%, Q4 Diagnostics +7%, Life Sciences flat. 2026 guide: 2-3% organic, $2.96-2.99B revenue.
AI Expansion: Launch of Signals Xynthetica AI platform with Lilly collaboration.
Share Buybacks: $800M in 2025, total $1.5B since 2023.
China Risks: Diagnostics China business <5% of revenue, cautious on DRG-related volumes.
2026 EPS: $5.35-5.45, with 28% operating margin and 1% FX tailwind.

Earnings

EPS

Revenue

Revenue & Expenses

RVTY has released its 2025 Q4 earnings report, with revenue of 772.06M, reflecting a YoY change of 5.85%, and net profit of 98.36M, showing a YoY change of 3.93%. The Sankey diagram below clearly presents RVTY's revenue sources and cost distribution.

Key Indicators

Revvity (RVTY) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Revvity (RVTY)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Revvity (RVTY)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Revvity (RVTY)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown